Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 3Terminated 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 35Thoracic 2Head & Neck 2NET 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 71Pituitary Neoplasms 47Thyroid Cancer, Papillary 28Multiple Endocrine Neoplasia Type 1 21Carcinoma, Neuroendocrine 21Pheochromocytoma 18Paraganglioma 14Thyroid Neoplasms 13Carcinoid Tumor 13Neoplasm Metastasis 12Differentiated Thyroid Cancer 12Adrenocortical Carcinoma 11Neoplasms 10Thyroid Carcinoma, Anaplastic 9Pancreatic Neoplasms 8Insulinoma 8Adrenal Gland Neoplasms 8Pituitary Diseases 6Lung Neoplasms 6Hyperaldosteronism 6Gastro-enteropancreatic neuroendocrine tumor 6Acromegaly 6Stomach Neoplasms 5Prostatic Neoplasms 5Prolactinoma 5Head and Neck Neoplasms 5Carcinoma, Hepatocellular 5Breast Neoplasms 5Adrenocortical Adenoma 5Adenoma, Islet Cell 5

Interventions

anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Digestive System Neoplasms × Endocrine × Clear all
NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡